Evidence map›Paper›PMID 27183377›Full record

ArticleJournal of medical virology2016

Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.

Gouda Kamel Helal, Magdy Abdelmawgoud Gad, Mohamed Fahmy Abd-Ellah, Mahmoud Saied Eid

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04340349 (Low-dose Hydroxychloroquine and Bromhexine), which is not on this map. Cited by 23 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 6 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04340349 early_phase1unknown statusnot on this mapstarted 2021, after this paper: background citation

Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)

TypeinterventionalSponsorInstituto Nacional de RehabilitacionRan2021 to 2021Enrolled214ConditionsHydroxychloroquine, Antimalarials, Enzyme Inhibitors, Antirheumatic AgentsArmsHydroxychloroquine Sulfate, Bromhexine 8 MG
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 6 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2020
    Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Medicina (Kaunas, Lithuania) · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Of chloroquine and COVID-19.Antiviral research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Gouda Kamel HelalFaculty of Pharmacy, Al-Azhar University, Cairo, Egypt. goudahelal@gmail.com.
Magdy Abdelmawgoud GadFaculty of Medicine, Benha University, Benha, Egypt.
Mohamed Fahmy Abd-EllahFaculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Mahmoud Saied EidFaculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Al-Azhar University · EGBenha University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic effect of pegylated interferon (peg-IFN) alfa-2a combined with ribavirin (RBV) on chronic hepatitis C Egyptian patients is low and further efforts are required to optimize this therapy for achievement of higher rates of virological response. This study aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) in combination with pegylated interferon plus ribavirin on early virological response (EVR) in chronic hepatitis C Egyptian patients. Naïve 120 Egyptian patients with chronic hepatitis C virus infection were divided into two groups. Group 1 have administered the standard of care therapy (pegylated interferon alfa-2a plus ribavirin) for 12 weeks, (n = 60). Group 2 have administered hydroxychloroquine plus standard of care therapy for 12 weeks, (n = 60). Therapeutics included hydroxychloroquine (200 mg) oral twice daily, peginterferon alfa-2a (160 μg) subcutaneous once weekly and oral weight-based ribavirin (1000-1200 mg/day). Baseline characteristics were similar in the two groups. The percentage of early virological response was significantly more in patients given the triple therapy than in patients given the standard of care [54/60 (90%) vs. 43/60 (71.7%); P = 0.011; respectively]. Biochemical response at week 12 was also significantly higher in patients given the triple therapy compared with the standard of care [58/60 (96.7%) vs. 42/60 (70%); P < 0.001; respectively]. Along the study, the observed adverse events were mild and similar across treatment groups. Addition of hydroxychloroquine to pegylated interferon plus ribavirin improves the rate of early virological and biochemical responses in chronic hepatitis C Egyptian patients without an increase in adverse events. J. Med. Virol. 88:2170-2178, 2016. © 2016 Wiley Periodicals, Inc.

Indexed as

Antiviral AgentsDrug Administration ScheduleDrug Therapy, CombinationEgyptFemaleGenotypeHepacivirusHepatitis C, ChronicHumansHydroxychloroquineInterferon-alphaMalePolyethylene GlycolsRecombinant ProteinsRibavirinRNA, ViralAntiviral AgentsHydroxychloroquineInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRibavirinRNA, Viralbiochemical responseearly virological responsehepatitis C Egyptian patientshydroxychloroquinepegylated interferonribavirin

Identifiers

PMID27183377
PMCPMC7167065
OpenAlexW2404131118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.